Results 1 to 10 of about 30,900 (164)
A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib [PDF]
Clinical Case Reports, 2022 Patients with chronic myelogenous leukemia (CML) harboring the T315I mutation who progress to blast phase CML while on ponatinib may be successfully treated with asciminib monotherapy following induction therapy with cytotoxic chemotherapy.
Sarah Tomassetti, Jennifer Lee, Xin Qing
doaj +2 more sources
A label free chemoproteomic-based platform to disclose cannabidiol molecular mechanism of action on chronic myelogenous leukemia cancer cells [PDF]
HeliyonThe discovery of the interactome of cannabidiol (CBD), a non-psychoactive cannabinoid from Cannabis sativa L., has been here performed on chronic myelogenous leukemia cancer cells, using an optimized chemo-proteomic stage, which links Drug Affinity ...
Sara Ceccacci +8 more
doaj +1 more source
Granulocytic Sarcoma with Compressive Myelopathy: A Rare Presentation of Chronic Myelogenous Leukemia [PDF]
Journal of Clinical and Diagnostic Research, 2014 Granulocytic sarcoma occurs most commonly in acute myelogenous leukemia. The appearance of granulocytic sarcoma in chronic myelogenous leukemia signals accelerated phase/ blast transformation.
Abhijeet P. Ganapule +4 more
doaj +1 more source
Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia
Clinical Case Reports, 2021 Gastrointestinal manifestations of leukemias have been well recognized. Typically, acute leukemias cause typhlitis or appendicitis more commonly than chronic leukemias.
Rita Ahmad +6 more
doaj +1 more source
Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
Онкогематология, 2015 The article presents example of modeling for pharmacoeconomical-founded choice of chronic myelogenous leukemia treatment strategy related to therapeutic efficacy and economical rationality. The economic model of chronic myelogenous leukemia diagnosis and
V. A. Shuvaev +3 more
doaj +3 more sources
Dasatinib: ten years of clinical practice worldwide
Онкогематология, 2016 The article contains results of meta-analysis of experience in use of second-generation tyrosine kinase inhibitors – dasatinib. The results of clinical trials dasatinib therapy in chronic myelogenous leukemia imatinib-resistant or intolerant patients are
K. M. Abdulkadyrov +2 more
doaj +1 more source
Haematologica, 2013 Second generation tyrosine kinase inhibitors have recently been introduced as first-line treatment for chronic phase chronic myelogenous leukemia. We aimed to evaluate the efficacy and safety of 2nd generation tyrosine kinase inhibitors versus imatinib ...
Ronit Gurion +9 more
doaj +1 more source
Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy
Case Reports in Cardiology, 2018 Decitabine is a pyrimidine analogue of nucleoside cytidine, used for the treatment of myelodysplastic syndromes, chronic myelogenous leukemia, and acute myelogenous leukemia.
Pradyumna Agasthi +4 more
doaj +1 more source
Indian Journal of Pathology and Microbiology, 2013 Chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different and common hematological neoplasms. Their coexistence is rare, especially CLL developing in a patient of CML. Till date, only a few cases are reported and all had
Narender Kumar +3 more
doaj +1 more source
Haematologica, 2013 The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this mutation on survival in early stages of disease, in chronic phase, has never been detailed.
Franck E. Nicolini +24 more
doaj +1 more source